VivoSeq
Other

Intensity-Modulated Radiation Therapy

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Intensity-modulated Radiation Therapy is an early-stage landscape with 0 programs across 1 company. The most active players are Radiation Therapy Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed7 · 78%
Terminated2 · 22%

Clinical Trials

Trial Activity

9 trials

Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
Completed·Radiation Therapy Oncology Group logoRadiation Therapy Oncology Group·Phase 2·NCT00613080·79 enrolled
Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00423930·44 enrolled
Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02282371·16 enrolled
Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
Completed·EEmory University·Phase 2·NCT03521570·62 enrolled
Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer
Completed·National Cancer Institute (NCI)·Phase 1·NCT01935921·19 enrolled
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
Completed·NRG Oncology·Phase 2·NCT02254278·316 enrolled
Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer
Completed·Radiation Therapy Oncology Group logoRadiation Therapy Oncology Group·Phase 2·NCT00423293·63 enrolled
Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
Terminated·—·Phase 1/2·NCT00540995·25 enrolled
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
Terminated·WWake Forest University Health Sciences·Phase 1/2·NCT00573989·27 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)